The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Seminars in Oncology

• Publication date

  2003-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/SONC.2003.50027PMID 12644979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

  2012cited by this paper
• The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study

  2004cited by this paper
• Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer

  2004cited by this paper
• Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

  2002cited by this paper
• ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

  2002cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression

  2001cited by this paper
• Studies of epidermal growth factor receptor inhibition in breast cancer.

  2001cited by this paper
• Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

  2001cited by this paper
• Cancer treatment in the STI571 era: what will change?

  2001cited by this paper
• The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

  2001cited by this paper
• Receptor tyrosine kinase signalling as a target for cancer intervention strategies.

  2001cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

  2001cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

  2000cited by this paper
• Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.

  2000cited by this paper
• Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.

  2000cited by this paper
• HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.

  2000cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• ZD1839 ('Iressa') as an anticancer agent.

  2000cited by this paper
• Development of inhibitors for protein tyrosine kinases

  2000cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

  2000cited by this paper
• EGF receptor.

  1999cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999cited by this paper
• Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.

  1999cited by this paper
• Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

  1998cited by this paper
• EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.

  1998cited by this paper
• Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

  1998cited by this paper
• Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

  1998cited by this paper
• Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer.

  1998cited by this paper
• c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.

  1998cited by this paper
• EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma

  1998cited by this paper
• Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma

  1997cited by this paper
• Expression of Epidermal Growth Factor‐Related Proteins and Epidermal Growth Factor Receptor in Common Epithelial Ovarian Tumors

  1997cited by this paper
• Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer.

  1997cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: a comparison of immunohistochemical method versus ligand binding assay.

  1997cited by this paper
• Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

  1996cited by this paper
• Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

  1996cited by this paper
• Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium.

  1996cited by this paper
• The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

  1996cited by this paper
• All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*)

  1996cited by this paper
• Patterns of epidermal growth factor receptor amplification in malignant gliomas.

  1996cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.

  1996cited by this paper
• Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.

  1995cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

  1995cited by this paper
• Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

  1995cited by this paper
• Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

  1995cited by this paper
• Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.

  1994cited by this paper
• Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma.

  1994cited by this paper
• Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.

  1994cited by this paper
• Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members

  1994cited by this paper
• The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer

  1993cited by this paper
• Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

  1993cited by this paper
• Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness.

  1993cited by this paper
• Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

  1993cited by this paper
• The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival.

  1993cited by this paper
• Structural alterations of the epidermal growth factor receptor gene in human gliomas.

  1992cited by this paper
• Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer.

  1992cited by this paper
• The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

  1992cited by this paper
• Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

  1991cited by this paper
• Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.

  1991cited by this paper
• Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung.

  1990cited by this paper
• The epidermal growth factor receptor and the prognosis of bladder cancer

  1990cited by this paper
• Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.

  1989cited by this paper
• Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects.

  1987cited by this paper
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

  1984cited by this paper

• Photophysical and electrochemical behaviour of ferrocene–triazole–BODIPY conjugate: Experimental and theoretical investigations

  2026cites this paper
• LINC01063 promotes colon cancer progression via the miR-134-5p/KRAS axis and serves as a prognostic biomarker

  2025cites this paper
• Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report

  2025cites this paper
• Dual topoisomerase IIα/EGFR-TK inhibitors: Synthesis, biological evaluation, and in silico studies of new thiadiazolo[3,2-a]pyrimidinone derivatives as potential anticancer agents.

  2025cites this paper
• Unraveling the mechanism of microRNA-134 in colon cancer progression: targeting KRAS and PIK3CA for cell cycle control and histone deacetylase regulation.

  2024cites this paper
• Recent Developments in Nanotechnology and Immunotherapy for the Diagnosis and Treatment of Pancreatic Cancer.

  2024cites this paper
• Identification of novel c-Kit inhibitors from natural sources using virtual screening and molecular dynamics simulations

  2023cites this paper
• Epidermal Growth Factor Receptor Inhibiting 4‐Aminoquinazolines as Promising Anticancer Agents: A Patent Review (2000‐Present)

  2023cites this paper
• Therapeutic potential of EGFR/mTOR/Nf-kb targeting small molecule for the treatment of non-small cell lung cancer.

  2023cites this paper
• Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule

  2022cites this paper
• Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine

  2022cites this paper
• The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines

  2021cites this paper
• Complementarity principle in terms of electron density for the study of EGFR complexes.

  2021cites this paper
• Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, accepted inhibits colorectal cancer stem cell growth.

  2021cites this paper
• Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy

  2020influential citation
• Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

  2020cites this paper
• Classical and Non-Classical Progesterone Signaling in Breast Cancers

  2020cites this paper
• Role of membrane lipids in colon differentiation unravelled by mass spectrometry imaging: arachidonic acid beyond inflammation

  2020cites this paper
• Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.

  2020cites this paper
• Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review

  2020cites this paper
• Cancer Imaging with Radiolabeled Monoclonal Antibodies

  2020cites this paper
• Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells

  2020cites this paper
• Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

  2019cites this paper
• miR-133b inhibits cell proliferation, migration and invasion of esophageal squamous cell carcinoma by targeting EGFR.

  2019cites this paper
• A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy.

  2019cites this paper
• Photonic modulation of epidermal growth factor receptor halts receptor activation and cancer cell migration

  2018cites this paper
• PKG II effectively reversed EGF‐induced protein expression alterations in human gastric cancer cell lines

  2018cites this paper
• Determination of Changes in the Expression of MIR-212 and EGFR Genes in Clinical Samples from Areas Infected with Trichophyton rubrum Compared with Non-Infected Areas

  2018cites this paper
• Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors

  2018cites this paper
• The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells

  2018cites this paper
• The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance

  2018cites this paper
• Novel Treatments for Advanced Cholangiocarcinoma

  2018cites this paper
• Boeravinone B a natural rotenoid exerts anticancer activity via inducing internalization and degradation of inactivated EGFR and ErbB2 in human colon cancer cells.

  2018cites this paper
• State of the art in anti-cancer mAbs

  2017cites this paper
• A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks

  2017cites this paper
• NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib

  2017cites this paper
• Inhibition of EGF-induced migration and invasion by sulfated polysaccharide of Sepiella maindroni ink via the suppression of EGFR/Akt/p38 MAPK/MMP-2 signaling pathway in KB cells.

  2017cites this paper
• EGFR signaling pathways are wired differently in normal 184A1L5 human mammary epithelial and MDA-MB-231 breast cancer cells

  2017cites this paper
• Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.

  2017cites this paper
• The Rice Receptor-Like Kinases DWARF AND RUNTISH SPIKELET1 and 2 Repress Cell Death and Affect Sugar Utilization during Reproductive Development

  2017cites this paper
• Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.

  2017cites this paper
• DNA Mutations May Not Be the Cause of Cancer

  2017cites this paper
• Sprouting strategies and dead ends in anti-angiogenic targeting of NETs.

  2017cites this paper
• Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c‐Met‐Mediated Epithelial‐to‐Mesenchymal Transition

  2017cites this paper
• Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro

  2017cites this paper
• Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients

  2016cites this paper
• Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer.

  2016cites this paper
• miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6

  2016cites this paper
• Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas.

  2016cites this paper
• 2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase.

  2016cites this paper
• [Trastuzumab - a monoclonal antibody - and dendrimers in a targeted therapy for breast cancer].

  2015cites this paper
• mAb806 binding to epidermal growth factor receptor: a computational study

  2015cites this paper
• Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions

  2015cites this paper
• In vivo Anti-Tumour Activity of Novel 2, 3, 7 Trisubstituted Quinazoline Derivatives

  2015cites this paper
• IDENTIFICATION OF POTENTIAL NOVEL EGFR INHIBITORS USING A COMBINATION OF PHARMACOPHORE AND DOCKING METHODS

  2015cites this paper
• Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids?

  2015cites this paper
• Honokiol from Magnolia spp. induces G1 arrest via disruption of EGFR stability through repressing HDAC6 deacetylated Hsp90 function in lung cancer cells

  2015cites this paper
• A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.

  2015cites this paper
• Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies

  2014cites this paper
• Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry

  2014cites this paper
• Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.

  2014cites this paper
• Chronopharmacology and Mechanism of Antitumor Effect of Erlotinib in Lewis Tumor-Bearing Mice

  2014cites this paper
• Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis

  2014cites this paper
• Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen

  2014cites this paper
• Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output

  2014cites this paper
• Surgery, wound healing, and metastasis: recent insights and clinical implications.

  2014cites this paper
• Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models.

  2013cites this paper
• A critical review of lipid-based nanoparticles for taxane delivery.

  2013cites this paper
• An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments

  2013cites this paper
• Nanoparticles for Improving Cancer Diagnosis.

  2013cites this paper
• The Role of Versican in Modulating Breast Cancer Cell Self-renewal

  2013cites this paper
• Psoriasis Induced by Trastuzumab (Herceptin®)

  2013cites this paper
• Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.

  2013cites this paper
• Multifunctional magnetic resonance imaging probes.

  2013cites this paper
• Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors

  2013cites this paper
• Snail Induces Mesenchymal Transition and Promotes EGFR TKI Resistance in NSCLC Cells Harboring EFGR Kinase Domain Mutations

  2013influential citation
• Isogenic human mammary epithelial cell lines: novel tools for target identification and validation

  2013cites this paper
• Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review

  2013cites this paper
• Autotaxin and lysophosphatidic acid signalling in lung pathophysiology

  2013cites this paper
• Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

  2013cites this paper
• MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer

  2013cites this paper
• Regulation of epidermal growth factor receptor signaling by plasmid-based microRNA-7 inhibits human malignant gliomas growth and metastasis in vivo.

  2013cites this paper
• Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents

  2013cites this paper
• Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics

  2013cites this paper
• Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

  2013cites this paper
• Cancer-Specific Ligand–Receptor Interactions

  2013cites this paper
• Target-specific Tc(CO)3-complexes for in vivo imaging

  2013cites this paper
• Mutants Is Associated with Asymmetric Dimerization Derived EGF Receptor − Cetuximab Response of Lung Cancer

  2013cites this paper
• Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells

  2013cites this paper
• Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models 1

  2013cites this paper
• Chapter 5 – Biologics and Their Interactions with Radiation

  2012cites this paper
• Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

  2012cites this paper
• Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases

  2012cites this paper
• Labeling of EGFR inhibitor to prepare a potential SPECT agent for molecular imaging of breast cancer via iodine-bromine exchange

  2012cites this paper
• Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy

  2012cites this paper
• Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma

  2012cites this paper
• Synthesis of furo[2,3-d]pyrimidines, thieno[2,3- d]pyrimidines, pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolates, receptor tyrosine kinase (RTK) inhibitors and antimitotic agents

  2012cites this paper
• 20 Panitumumab for the Treatment of Metastatic Colorectal Cancer

  2012cites this paper
• Novel targeted agents for gastric cancer

  2012cites this paper
• EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia

  2012cites this paper